Evaluation of efficacy and safety of oral terbinafine and itraconazole combination therapy in the management of superficial dermatophytosis- A Randomised Clinical Double blinded Trial
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 5, Pages 177-182
AbstractBackground: Common fungal infections like dermatophytosis are brought on by Trichophyton, Epidermophyton, and Microsporum species. All patients with dermatophytosis should get a combination of systemic and topical antifungal medication, with the exception of those who have localised naive tinea. Study participants took oral terbinafine and itraconazole to see how well they worked together against superficial dermatophytosis.
Materials and Methods: For this randomised clinical trial, 50 people with superficial dermatophytosis were divided into two groups. The study was conducted in the Department of Dermatology's Outpatient Department from December 2021 to May 2022. Treatment in Group I consisted of four weeks on Terbinafine 250 mg OD and 200 mg OD itraconazole, whereas in Group II, just Terbinafine 250 mg OD was given. As a result, the patients were seen every two weeks and given the necessary diagnostics. The statistical analysis was performed using SPSS version 16.0, the Statistical Package for the Social Sciences.
Results: Itraconazole containing group reported a better clinical cure rate than the griseofulvin containing group (p<0.05). Neither of the combination showed effectiveness against tinea infections pre-treated with topical steroid containing formulations.
Conclusion: When terbinafine and itraconazole are combined, a greater clinical cure rate is achieved than when terbinafine is used alone.
- Article View: 112
- PDF Download: 103